Sidney Kimmel Cancer Center at Jefferson | Strategic Alliance Partners

May 08, 2023

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

May 01, 2023

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

May 01, 2023

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

April 24, 2023

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

April 24, 2023

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

April 17, 2023

Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.

April 17, 2023

Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.

March 02, 2023

Edith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

December 16, 2022

Alessandro Fatatis, MD, PhD, has been named Associate Director for Basic Research at Jefferson Health’s Sidney Kimmel Cancer Center.

October 25, 2022

Jefferson Health’s Sidney Kimmel Cancer Center welcomes transdisciplinary population health researcher Terry Hyslop, PhD, as Co-leader of the Cancer Risk and Control Program.

July 14, 2022

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

June 22, 2022

The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.

June 15, 2022

The Sidney Kimmel Cancer Center– Jefferson Health has appointed Ana Maria Lopez, MD, MPH, MACP, FRCP, as Associate Director for Diversity, Equity, and Inclusion.

June 06, 2022

Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of older adults who develop cancer, and challenges stemming from the COVID-19 pandemic that have affected the care of geriatric patients with cancer, such as the strain put on caregivers and the shift to telemedicine.

March 16, 2022

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

February 28, 2022

One of the primary goals of the ECOG-ACRIN Health Equity Committee is to continue addressing disparities that limit the representation of minority populations in cancer clinical trials.

January 21, 2022

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.

January 19, 2022

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shares the inspiration behind the ECOG-ACRIN Health Equity Committee, efforts made to address health disparities, how the pandemic has impacted screening and care in the cancer field, and what needs to be done to get back on track.

January 13, 2022

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

December 20, 2021

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.